Form 4: Kymera Therapeutics Executive Noah Goodman Acquires Stock and Options

Chief Business Officer Noah Goodman of Kymera Therapeutics acquired 50,000 shares of common stock and options to purchase 100,000 shares, according to a recent SEC filing.

Summary

• Noah Goodman, Chief Business Officer of Kymera Therapeutics, acquired 50,000 shares of common stock on April 8, 2025.
• These shares were acquired as restricted stock units (RSUs), each representing a right to receive one share of Kymera's common stock upon vesting.
• The RSUs vest in four equal annual installments starting April 8, 2025, contingent upon continued employment.
• Goodman also acquired options to purchase 100,000 shares of common stock at an exercise price of $21.05 on April 8, 2025.
• 25% of the options vest on April 8, 2026, with the remaining portion vesting in 36 equal monthly installments, also subject to continued employment.
• Following these transactions, Goodman directly owns 50,081.438 shares of common stock and options for 100,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive. It doesn't inherently indicate positive or negative news about the company's performance, but rather reflects standard compensation practices.

Positives

• The acquisition of stock and options by a key executive could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the reporting person's continued employment with Kymera Therapeutics.

Industry Context

This type of filing is standard for publicly traded companies and reflects executive compensation practices within the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the biotechnology industry to incentivize performance and align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules and exercise prices are generally benchmarked against industry standards to attract and retain talent.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.
• Employees may view the equity grants as a positive aspect of the company's compensation structure.

Key Dates

Keywords

Kymera Therapeutics, Noah Goodman, stock options, RSUs, beneficial ownership, Form 4, KYMR, executive compensation